ArticleFrontiers in immunology2026
Trigger finger and the risk of systemic inflammatory and autoimmune rheumatic diseases: real-world evidence.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trigger finger (TF) is a common hand disorder traditionally viewed as a localized mechanical condition. Recent evidences suggests potential links between tenosynovial pathology and systemic inflammatory diseases, especially rheumatoid arthritis, though large-scale longitudinal data remain limited. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network. Adults diagnosed with TF between 2005 and 2018 were identified and compared with individuals undergoing routine health evaluations without TF. Patients with prior malignancy, systemic rheumatic diseases, or death before index were excluded. One-to-one propensity score matching balanced demographics, comorbidities, healthcare utilization, medications, and socioeconomic factors. The primary outcomes were incident systemic autoimmune and inflammatory rheumatic diseases, including inflammatory arthritis and connective tissue disorders. We estimated hazard ratios with 95% confidence intervals. Robustness was assessed through sensitivity analyses incorporating alternative matching strategies, extended washout periods, varying follow-up durations, and stricter exposure definitions, alongside subgroup analyses by age and sex. As validation, data from US Collaborative Network were also applied for analysis. Results: After matching, 82,566 patients were included in each cohort. TF was associated with increased risks of ankylosing spondylitis (HR 1.973, 95% CI 1.377-2.828), rheumatoid arthritis (HR 1.604, 95% CI 1.287-1.998), psoriatic arthritis (HR 1.832, 95% CI 1.428-2.352), and gout (HR 1.152, 95% CI 1.053-1.261). Elevated risks were also observed for systemic lupus erythematosus (HR 1.460, 95% CI 1.146-1.858) and Sjögren syndrome (HR 1.314, 95% CI 1.077-1.604). Associations remained consistent across most sensitivity analyses, including extended washout periods and alternative cohort definitions. Subgroup analyses demonstrated similar patterns across age and sex strata. Conclusions: TF was associated with systemic autoimmune and inflammatory rheumatic diseases. Current findings support a potential link between localized tendon pathology and broader systemic inflammatory processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.